MainboardGMP
LIVE
LIVE GMP
MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·
Home › IPOs › Glenmark Life Sciences Ltd.
GL
Glenmark Life Sciences Ltd.
CLOSED NSE & BSE Bookbuilding IPO Fresh Capital-cum-Offer for Sale Glenmark Life Sciences IPO GMP
GREY MARKET PREMIUM
₹ 0
No premium data
EST. LISTING PRICE
₹720
Issue Price: ₹ 720
Issue Price
₹720
Face Value
₹2
Lot Size
20 shares
Open Date
27 Jul 2021
Close Date
29 Jul 2021
Allotment
03 Aug 2021
Listing Date
06 Aug 2021
Exchange
NSE & BSE
Glenmark Life Sciences IPO About the Company

Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Competitive strengths

  • Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
  • Export products in Europe, Latin America, North America, Japan, and the rest of the world.
  • Strong relationship with leading global generic companies.
  • Proven track record of strong financial performance.
  • High-quality product manufacturing with R&D infrastructure.
...read more
Glenmark Life Sciences IPO Objects of the Issue
Purpose Amount (₹ Cr)
1 Payment of outstanding purchase consideration to the Promoter for thespin-off of the API business from the Promoter into our Companypursuant to the Business Purchase Agreementdated October 9, 2018 ₹800
2 Funding the capital expenditure requirements ₹153
3 General corporate purposes ₹58
Glenmark Life Sciences IPO Lead Managers
BOFA Securities India Ltd. BOB Capital Markets Ltd. Dam Capital Advisors Ltd. Goldman Sachs (India) Securities Pvt.Ltd. Kotak Mahindra Capital Co.Ltd. SBI Capital Markets Ltd.
Financial Summary Amount in Crore
Metric 31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 1,997 1,726 1,475
Revenue 1,886 1,549 887
PAT 352 313 196
Issue Details
Total Shares Offered
21,022,222 (100%)
Pre-Issue Shareholding
107,804,950 shares
Post-Issue Shareholding
122,527,172 shares
UPI Mandate
29 Jul 2021
IPO Analytics Dashboard
LIVE
Glenmark Life Sciences IPO GMP Insights
👤
Retail Demand
Good
💼
HNI Interest
Good
🏦
QIB Demand
Strong
📊
Valuation
Moderate
Glenmark Life Sciences IPO GMP Strength Score
7 / 10 Good
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Glenmark Life Sciences IPO Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
🏦 QIB — 10,511,110 (50%) —
💼 NII / HNI — 3,153,334 (15%) —
👤 Retail (RII) — 7,357,778 (35%) —
Σ Total — 21,022,222 (100%) —

* Amount calculated at upper price band (₹720) ·  ** Total includes all investor categories

Subscription Overview Share allocation by investor category
🏦
QIB ? 10,511,110 (50%)
50%
💼
NII / HNI ? 3,153,334 (15%)
15%
👤
Retail (RII) ? 7,357,778 (35%)
35%
Total Shares Offered 21,022,222 (100%)
Glenmark Life Sciences IPO Application Sizing Minimum investment by category
👤 Retail Investors ?
Min. Lots 1
Shares / Lot 20
Min. Investment ₹14,400
💼 HNI Investors ?
Min. Lots 14
Min. Shares 280
Min. Investment ₹201,600
🏛️ bHNI (>₹10L) ?
Min. Lots 70
Min. Shares 1,400
Min. Investment ₹1,008,000
Glenmark Life Sciences IPO Timeline & Key Dates
  1. 1 💳 Initiation of Refund 04 Aug 2021
  2. 2 📂 Credit of Shares to Demat 05 Aug 2021
  3. 3 🔒 Lock-in Period (30%) September 2, 2021
  4. 4 🔒 Lock-in Period (50%) November 1, 2021
Investor Interpretation
  • Retail allocation is good at 35% of the total offering.
  • HNI/NII demand is good at 15%.
  • Institutional (QIB) interest is strong at 50%.

This IPO shows moderate investor interest. Review financial details and compare valuation with industry peers before investing.

STOCK PRICE HISTORY  ·  NSE
—
Issue Price: ₹ 720  ·  Symbol: —
H —
L —
O —
Glenmark Life Sciences IPO Company Info
📍 Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413 213, Mohol, Maharashtra
Visit Website
Glenmark Life Sciences IPO Registrar
Kfin Technologies Ltd.
Check Allotment Status
Glenmark Life Sciences IPO FAQs
Glenmark Life Sciences IPO has already listed. Its last recorded GMP was ₹0. GMP is only indicative and never a guarantee of listing gains.
The issue price of Glenmark Life Sciences IPO is ₹720 per share. One lot has 20 shares, so the minimum investment is about ₹14,400. It is a Fresh Capital-cum-Offer for Sale issue.
Glenmark Life Sciences IPO opened on 27 Jul 2021 and closed on 29 Jul 2021. Allotment is tentatively finalised on 03 Aug 2021. Shares are listed on NSE & BSE on 06 Aug 2021.
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and di…
As per the offer document, Glenmark Life Sciences plans to use the IPO proceeds for: 1 Payment of outstanding purchase consideration to the Promoter for thespin-off of the API business from the Promoter into our Companypursuant to the Business Purchase Agreementdated October 9, 2018 (₹800); 2 Funding the capital expenditure requirements (₹153); 3 General corporate purposes (₹58).
The lead managers of Glenmark Life Sciences IPO are BOFA Securities India Ltd., BOB Capital Markets Ltd., Dam Capital Advisors Ltd., Goldman Sachs (India) Securities Pvt.Ltd., Kotak Mahindra Capital Co.Ltd., SBI Capital Markets Ltd..
Glenmark Life Sciences IPO is proposed to list on NSE & BSE; it is a Bookbuilding IPO and the issue is a Fresh Capital-cum-Offer for Sale.
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.